Brief: Spero Therapeutics Provides Corporate Update And 2024 Outlook

Spero Therapeutics

05/01/2024 13:54

Jan 5 (Reuters) - Spero Therapeutics Inc  SPRO.O :
    * SPERO THERAPEUTICS PROVIDES CORPORATE UPDATE AND 2024
OUTLOOK
    * UPDATED PRELIMINARY CASH BALANCE AND CASH RUNWAY GUIDANCE
INTO
LATE 2025
    * INITIATED DOSING IN PIVOT-PO PHASE 3 TRIAL FOR TEBIPENEM
HBR IN
CUTI PATIENTS
    * ENTITLED TO RECEIVE $95 MILLION IN DEVELOPMENT MILESTONES,
PAYABLE OVER TWO YEARS, AS PART OF GSK LICENSE AGREEMENT
    * IN 2H 2024, EXPECT TO PROVIDE PHASE 2A TOPLINE
PROOF-OF-CONCEPT
DATA FROM OUR WHOLLY-OWNED LEAD PROGRAM SPR720 IN NTM-PD
PATIENTS

Source text for Eikon:  ID:nGNX1KyLTp 
Further company coverage:  SPRO.O 

 ((Reuters.Briefs@thomsonreuters.com;))